IMAGE:Nucleic Acid Therapeutics is an authoritative, peer-reviewed journal published bimonthly in print and online that focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids... view more <\/p>\n
Credit: Mary Ann Liebert, Inc., publishers <\/p>\n
New Rochelle, NY, January 27, 2015--Therapeutic oligonucleotide analogs represent a new and promising family of drugs that act on nucleic acid targets such as RNA or DNA; however, their effectiveness has been limited due to difficulty crossing the cell membrane. A new delivery approach based on cell-penetrating peptide nanoparticles can efficiently transport charge-neutral oligonucleotide analogs into cells, as reported in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Nucleic Acid Therapeutics website. <\/p>\n
In the article, \"Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides,\" Peter Jrver and coauthors, Cambridge Biomedical Campus (U.K.), Karolinska University Hospital (Huddinge, Sweden), Stockholm University (Sweden), Alexandria University (Egypt), and University of Oxford (U.K.), note that while delivery systems exist to facilitate cell entry of negatively charged oligonucleotide drugs, these approaches are not effective for charge-neutral oligonucleotide analogs. The authors describe lipid-functionalized peptides that form a complex with charge-neutral morpholino oligonucleotides, enabling them to cross into cells and retain their biological activity. <\/p>\n
\"The exploitation of phosphorodiamidate morpholinos represents an exciting approach to treating a number of therapeutic targets,\" says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI. \"This paper suggests an intriguing but practical approach to solving the lack of a convenient non-covalent delivery system.\" <\/p>\n
### <\/p>\n
Nucleic Acid Therapeutics is under the editorial leadership of Editor-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center, Durham, NC, and Executive Editor Graham C. Parker, PhD. <\/p>\n
About the Journal <\/p>\n
Nucleic Acid Therapeutics is an authoritative, peer-reviewed journal published bimonthly in print and online that focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. Nucleic Acid Therapeutics is the official journal of the Oligonucleotide Therapeutics Society. Complete tables of content and a sample issue may be viewed on the Nucleic Acid Therapeutics website. <\/p>\n
About the Society <\/p>\n
<\/p>\n
More: <\/p>\n
Nanoparticles that deliver oligonucleotide drugs into cells described in Nucleic Acid Therapeutics<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" IMAGE:Nucleic Acid Therapeutics is an authoritative, peer-reviewed journal published bimonthly in print and online that focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids... view more Credit: Mary Ann Liebert, Inc., publishers New Rochelle, NY, January 27, 2015--Therapeutic oligonucleotide analogs represent a new and promising family of drugs that act on nucleic acid targets such as RNA or DNA; however, their effectiveness has been limited due to difficulty crossing the cell membrane. Continue reading